{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T01:09:54Z","timestamp":1788916194054,"version":"build-2803163510"},"reference-count":38,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T00:00:00Z","timestamp":1532476800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Janssen Scientific Affairs LLC (Titusville, New Jersey)","award":["CDA11-263"],"award-info":[{"award-number":["CDA11-263"]}]},{"name":"Veterans Affairs Health Services Research and Development Career Development"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clinthera.2018.07.011","type":"journal-article","created":{"date-parts":[[2018,8,23]],"date-time":"2018-08-23T01:10:42Z","timestamp":1534986642000},"page":"1496-1508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans"],"prefix":"10.1016","volume":"40","author":[{"given":"Maral","family":"DerSarkissian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kruti","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianne","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Lafeuille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Bhak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hellstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Bobbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Shiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C.","family":"El Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinong","family":"Young-Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2018.07.011_bib0001","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0003","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS medicine"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/oxfordjournals.schbul.a007071","article-title":"The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003","volume":"30","author":"Lehman","year":"2004","journal-title":"Schizophrenia bulletin"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900026304","article-title":"Treatment adherence and long-term outcomes","volume":"12","author":"Kane","year":"2007","journal-title":"CNS Spectrums"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0006","article-title":"Guideline Watch (September 2009): Practice guidelines for the treatment of patients with schizophrenia","author":"Dixon","year":"2009","journal-title":"American Psychiatric Association Practice Guidelines"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0007","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1176\/appi.ps.54.4.508","article-title":"An Economic review of compliance with medication therapy in the treatment of schizophrenia","volume":"54","author":"Thieda","year":"2003","journal-title":"Psychiatric services"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0008","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","article-title":"Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia","volume":"176","author":"Novick","year":"2010","journal-title":"Psychiatry research"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0009","doi-asserted-by":"crossref","first-page":"818","DOI":"10.4088\/JCP.v68n0601","article-title":"Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia","volume":"68","author":"Cooper","year":"2007","journal-title":"The journal of clinical psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0010","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4088\/JCP.v63n1007","article-title":"Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature","volume":"63","author":"Lacro","year":"2002","journal-title":"The journal of clinical psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0011","doi-asserted-by":"crossref","first-page":"754","DOI":"10.18553\/jmcp.2015.21.9.754","article-title":"Antipsychotic adherence and rehospitalization in schizophrenia patients receiving oral versus long-acting injectable antipsychotics following hospital discharge","volume":"21","author":"Marcus","year":"2015","journal-title":"Journal of managed care & specialty pharmacy"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0013","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4088\/JCP.14m09584","article-title":"Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study","volume":"76","author":"Alphs","year":"2015","journal-title":"The journal of clinical psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time to relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophrenia research"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0015","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3111\/13696998.2015.1033424","article-title":"Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder","volume":"18","author":"Joshi","year":"2015","journal-title":"Journal of medical economics"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0016","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.schres.2015.08.015","article-title":"Paliperidone palmitate versus oral antipsychotics in recently diagnosed schizophrenia","volume":"169","author":"Schreiner","year":"2015","journal-title":"Schizophrenia research"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0017","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4088\/JCP.14m09416","article-title":"Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder","volume":"76","author":"Fu","year":"2015","journal-title":"The Journal of clinical psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1477-7525-10-35","article-title":"Health-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off study","volume":"10","author":"Osborne","year":"2012","journal-title":"Health and quality of life outcomes"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/368687","article-title":"Treatment adherence with early prescription of long-acting injectable antipsychotics in recent-onset schizophrenia","volume":"2012","author":"Viala","year":"2012","journal-title":"Schizophrenia research and treatment"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.4088\/JCP.v65n0412","article-title":"Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone","volume":"65","author":"Nasrallah","year":"2004","journal-title":"The journal of clinical psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0021","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1017\/S1461145709000352","article-title":"Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs","volume":"12","author":"Potkin","year":"2009","journal-title":"haloperidol. International journal of neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0022","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/j.1524-4733.2008.00495.x","article-title":"Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study","volume":"12","author":"Alonso","year":"2009","journal-title":"Value in health"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0023","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial","volume":"72","author":"Berwaerts","year":"2015","journal-title":"JAMA psychiatry"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0024","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1080\/03007995.2017.1359516","article-title":"Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting","volume":"33","author":"Joshi","year":"2017","journal-title":"Current medical research and opinion"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0025","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/aje\/kwq433","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan","year":"2011","journal-title":"American journal of epidemiology"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0026","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"Journal of chronic diseases"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0027","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiology and drug safety"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0028","unstructured":"Elixhauser A, Steiner C, Kruzikas D. Health care Cost and Utilization Project (HCUP) Comorbidity Software. 2015. Rockville, Md: Agency for Health care Research and Quality. Available from: https:\/\/www.hcup-us.ahrq.gov\/toolssoftware\/comorbidity\/comorbidity.jsp#download.2"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0029","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2147\/PPA.S41609","article-title":"Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia","volume":"7","author":"Dilla","year":"2013","journal-title":"Patient preference and adherence"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0030","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1080\/13696998.2017.1351370","article-title":"Cost-effectiveness of 3-month paliperidone treatment for chronic schizophrenia in Spain","volume":"20","author":"Einarson","year":"2017","journal-title":"Journal of medical economics"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0031","first-page":"1","article-title":"Cost effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands","author":"Einarson","year":"2017","journal-title":"Journal of medical economics"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0033","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.2147\/NDT.S134287","article-title":"Efficacy and safety of paliperidone palmitate three monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study","volume":"13","author":"Savitz","year":"2017","journal-title":"Neuropsychiatric disease and treatment"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0034","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw018","article-title":"Efficacy and safety of paliperidone palmitate 3-month formulation for patients with schizophrenia: a randomized, multicenter, double-blind, noninferiority study","volume":"19","author":"Savitz","year":"2016","journal-title":"The international journal of neuropsychopharmacology"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0035","article-title":"Antipsychotic adherence and its correlation to health outcomes for chronic comorbid conditions","volume":"14:","author":"Farley","year":"2012","journal-title":"The primary care companion to CNS disorders"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0036","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1176\/appi.ps.201100328","article-title":"Adherence to antipsychotics and cardiometabolic medication: association with health care utilization and costs","volume":"63","author":"Hansen","year":"2012","journal-title":"Psychiatric services"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0037","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2008.11.007","article-title":"Recovery in the outpatient setting: 36- month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study","volume":"108","author":"Novick","year":"2009","journal-title":"Schizophrenia research"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0038","unstructured":"US Dept Veterans Affairs. Depart-ment of Veterans Affairs Statistics at a Glance. 2016. Available at: https:\/\/www.va.gov\/vetdata\/docs\/Quickfacts\/Homepage_slideshow_06_04_16.pdf. Accessed January 22, 2018"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0039","unstructured":"National Center for Veterans Analysis and Statistics. Profile of Veterans: 2015 Data from the American Community Survey. 2017."},{"key":"10.1016\/j.clinthera.2018.07.011_bib0040","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.2147\/NDT.S150568","article-title":"Role of 3-monthly long acting injectable paliperidone in the maintenance of schizophrenia","volume":"13","author":"Brasso","year":"2017","journal-title":"Neuropsychiatric disease and treatment"},{"key":"10.1016\/j.clinthera.2018.07.011_bib0041","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/NDT.S139633","article-title":"Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review","volume":"14","author":"Emsley","year":"2018","journal-title":"Neuropsychiatric disease and treatment"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291818303163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,19]],"date-time":"2018-12-19T14:54:16Z","timestamp":1545231256000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291818303163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0149291818303163"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.011","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2018.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}